4//SEC Filing
Friedman Charlene A 4
Accession 0001181431-13-014240
CIK 0001401923other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:16 PM ET
Size
24.7 KB
Accession
0001181431-13-014240
Insider Transaction Report
Form 4
Friedman Charlene A
VP President, Gen Counsel &Sec
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−74,744→ 0 totalExercise: $12.37Exp: 2017-07-23→ Common Stock (74,744 underlying) - Disposition from Tender
Common Stock
2013-03-01$25.00/sh−4,229$105,725→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−30,000→ 0 totalExercise: $13.12Exp: 2018-01-21→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−50,805→ 0 totalExercise: $10.37Exp: 2019-02-10→ Common Stock (50,805 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−27,500→ 0 totalExercise: $16.15Exp: 2021-01-25→ Common Stock (27,500 underlying) - Disposition to Issuer
Restricted Stock Unit (RSU)
2013-03-01−4,500→ 0 totalExp: 2015-01-26→ Common Stock (4,500 underlying) - Disposition to Issuer
Restricted Stock Unit (RSU)
2013-03-01−8,250→ 0 totalExp: 2016-01-25→ Common Stock (8,250 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−55,000→ 0 totalExercise: $16.19Exp: 2020-02-01→ Common Stock (55,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2013-03-01−32,500→ 0 totalExercise: $14.09Exp: 2022-01-24→ Common Stock (32,500 underlying)
Footnotes (10)
- [F1]These shares were tendered to Groundhog Acquisition, Inc. (the "Purchaser") pursuant to the Purchaser's offer to purchase all of the outstanding shares common stock (the "Common Stock") of MAP Pharmaceuticals, Inc. (the "Issuer") at a cash purchase price of $25.00 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase for Cash filed with the Securities and Exchange Commission on January 31, 2013 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of January 22, 2013, by and among Allergan, Inc. ("Parent"), the Purchaser and the Issuer (the "Merger Agreement"). Such shares were purchased by the Purchaser pursuant to the Tender Offer on March 1, 2013, which is also the date of the closing of a merger by and among Parent, the Purchaser and the Issuer (the "Effective Time").
- [F10]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $206,250.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
- [F2]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $943,844.81, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F3]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $356,400.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F4]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $743,277.15, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F5]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $484,550.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F6]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $243,375.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F7]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $354,575.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
- [F8]Each RSU represents a contingent right to receive one share of the Common Stock.
- [F9]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $112,500.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
Documents
Issuer
MAP Pharmaceuticals, Inc.
CIK 0001401923
Entity typeother
Related Parties
1- filerCIK 0001413748
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 8:16 PM ET
- Size
- 24.7 KB